A Prescription Drug User Fee Act target date of February 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

Please provide your email address to receive an email when new articles are posted on . Idebenone has a Prescription Drug User Fee Act date of Feb. 28, 2026. Positive results in the phase 3 RHODOS and ...

FDA grants Priority Review to idebenone for Leber Hereditary Optic Neuropathy (LHON), a disease for which there are no existing approved treatments in the U.S.; action date of February 28, 2026 PARMA, ...

NICE has endorsed idebenone (Raxone) on the NHS to treat Leber’s hereditary optic neuropathy in individuals aged 12 and over, offering hope to around 250 people Hundreds of adolescents and adults ...

The study found a median of 3.3 years between the initiation of GLP-1 RA use and the incidence of NAION. An increased risk for NAION was seen in association with 2 GLP-1 RAs: hazard ratios, 1.39 for ...

The use of GLP-1 receptor agonists, and particularly liraglutide, was associated with an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) during the first year of ...